Response outcomes and manner of progression after CAR T-cell therapy
| Response . | Value (n = 10) . | % . |
|---|---|---|
| Best systemic response | ||
| ORR | 8 | 80 |
| CR/sCR | 6 | 60 |
| VGPR | 1 | 10 |
| PR | 1 | 10 |
| SD | 1 | 10 |
| PD | 1 | 10 |
| Best MRD response | ||
| MRD negative | 4 | 40 |
| MRD positive | 2 | 20 |
| Not tested | 4 | 40 |
| CNS response by day 90 | ||
| Yes | 10 | 100 |
| No | 0 | 0 |
| Manner of progression after CAR T-cell therapy | ||
| CNS progression∗ | 4 | 40 |
| Systemic progression | 8 | 80 |
| Manner of identification of progression | ||
| Asymptomatic† | 5 | 50 |
| Symptomatic | 5 | 50 |
| Response . | Value (n = 10) . | % . |
|---|---|---|
| Best systemic response | ||
| ORR | 8 | 80 |
| CR/sCR | 6 | 60 |
| VGPR | 1 | 10 |
| PR | 1 | 10 |
| SD | 1 | 10 |
| PD | 1 | 10 |
| Best MRD response | ||
| MRD negative | 4 | 40 |
| MRD positive | 2 | 20 |
| Not tested | 4 | 40 |
| CNS response by day 90 | ||
| Yes | 10 | 100 |
| No | 0 | 0 |
| Manner of progression after CAR T-cell therapy | ||
| CNS progression∗ | 4 | 40 |
| Systemic progression | 8 | 80 |
| Manner of identification of progression | ||
| Asymptomatic† | 5 | 50 |
| Symptomatic | 5 | 50 |